Tolvaptan phosphate is a drug used for the treatment of cardiac edema. It is a

prodrug A prodrug is a medication or compound that, after intake, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Instead of administering a drug directly, a corresponding prodrug can be used to improve how the drug ...

tolvaptan Tolvaptan, sold under the brand name Samsca among others, is an aquaretic drug that functions as a selective, competitive vasopressin receptor 2 (V2) antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive hea ...

, formulated as the salt tolvaptan sodium phosphate, for

intravenous administration Intravenous therapy (abbreviated as IV therapy) is a medical technique that administers fluids, medications and nutrients directly into a person's vein. The intravenous route of administration is commonly used for rehydration or to provide nutri ...

. Tolvaptan phosphate is converted into the active drug tolvaptan in the human body following administration. It was developed by

Otsuka Pharmaceutical Co. (), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964. History OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an in ...

and was approved for use in Japan in 2022.

References

{{Cardiovascular-drug-stub Prodrugs Organophosphates Diuretics Chloroarenes Benzanilides Vasopressin receptor antagonists Benzazepanes